![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1574121
¼¼°èÀÇ AI Ȱ¿ë ÀÓ»ó½ÃÇè °ü¸® ½ÃÀå - Àü¸Á(2024-2029³â)AI-Powered Clinical Trial Management Market - Forecasts from 2024 to 2029 |
AI Ȱ¿ë ÀÓ»ó½ÃÇè °ü¸® ½ÃÀåÀº CAGR 22.50%·Î ¼ºÀåÇÏ¿© 2024³â 17¾ï 9,400¸¸ ´Þ·¯ ±Ô¸ð¿¡¼ 2029³â 49¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÇコÄÉ¾î ºÐ¾ßÀÇ AI Ȱ¿ë ½ÃÀåÀº ÁÖ¿ä ±â¾÷µéÀÇ AI µµÀÔÀ¸·Î Å©°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, AI ±â¹Ý ÀÓ»ó½ÃÇè °ü¸® ½ÃÀåÀº ȯÀÚ ¸ðÁý, µ¥ÀÌÅÍ ºÐ¼®, ÇÁ·ÎÅäÄÝ ÃÖÀûȸ¦ ÅëÇØ ÀÓ»ó½ÃÇèÀÇ ´Ù¾çÇÑ ´Ü°è¸¦ °¡¼ÓÈÇÏ°í °³¼±Çϰí, AI´Â ¹Ýº¹ÀûÀÎ ÀÛ¾÷À» ÀÚµ¿ÈÇÏ°í ¿¹ÃøÀû ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á ÀǾàǰ °³¹ßÀ» º¸´Ù È¿À²ÀûÀ̰í Àú·ÅÇÏ¸ç ºü¸£°Ô ÁøÇàÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÚµ¿ÈÇÏ°í ¿¹ÃøÀû ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á ÀǾàǰ °³¹ßÀ» º¸´Ù È¿À²ÀûÀ̰í, Àú·ÅÇϰí, ºü¸£°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀº ÀÇÇÐ ¿¬±¸ÀÇ Àüü ÇÁ·Î¼¼½º¸¦ º¯È½ÃÄÑ º¸´Ù Á¤È®ÇÏ°í ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Á¦¾àȸ»ç, ¿¬±¸±â°ü ¹× ÀÇ·á ¼ºñ½º Á¦°ø¾÷üÀÇ AI ±â¹Ý ¼Ö·ç¼Ç µµÀÔÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÏ¿© »óȲÀ» º¯È½ÃŰ°í ±Ã±ØÀûÀ¸·Î ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç Á¦°ø¾÷ü ½ÃÀåÀº ´Ù¾çÇÑ ´Ü°èÀÇ ÀÓ»ó½ÃÇèÀÇ È¿À²¼º°ú À¯È¿¼ºÀ» ³ôÀ̱â À§ÇØ AI ±â¹Ý Ç÷§ÆûÀÇ Ã¤ÅÃÀÌ È®´ëµÇ¸é¼ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå È®´ë¸¦ À̲ô´Â ¿äÀÎ Áß Çϳª´Â ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ Â÷¿øÀÇ Áö¿øÃ¥ÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó½ÃÇè¿¡¼ AI¿¡ ´ëÇÑ ÀνÄÀÌ °³¼±µÇ°í, ȯÀÚ ¼±º°, ½ÃÇè±â°ü ¼±Á¤, ½ÃÇè ¼³°è, ȯÀÚ ¸ð´ÏÅ͸µ µî ´Ù¾çÇÑ È°¿ëÀÌ °¡´ÉÇØÁö¸é¼ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
ÀΰøÁö´ÉÀÇ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ Àû¿ëÀÌ È°¹ßÇØÁö¸é¼ ¾à¹° ¼øÀÀµµ, ÀÓ»ó½ÃÇè ¼³°è, ÀÓ»ó½ÃÇè Ã¥ÀÓÀÚ ¹× ½ÃÇè±â°ü ¼±Á¤, ȯÀÚ ¸ð´ÏÅ͸µ µî Á¦¾à ¿¬±¸ Àü¿ëÀ¸·Î ¼³°èµÈ ´Ù¾çÇÑ ÀΰøÁö´É ¼Ö·ç¼ÇÀÌ Á¦°øµÇ¸é¼ ÀΰøÁö´É ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç Á¦°ø ¿µ¿ªÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. µî·Ï°ú ȯÀÚ Àû°Ý¼ºÀº ÀÓ»ó½ÃÇèÀÇ Àü¹ÝÀûÀÎ ¼º°ø¿¡ ¸Å¿ì Áß¿äÇÑ µÎ °¡Áö °úÁ¤ÀÔ´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é, ÀÓ»ó½ÃÇèÀÇ 30%´Â ȯÀÚ ¸ðÁý ½ÇÆÐ·Î ÀÎÇØ Á¶±â Á¾·áµÇ°í, 85%ÀÇ ÀÓ»ó½ÃÇèÀº ȯÀÚ ¸ðÁý Áß¿¡ ¿¬±âµÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Âµ¥, AI ¿ä¼Ò¸¦ °®Ãá Ç÷§ÆûÀº ÀÌ·¯ÇÑ À庮À» ³·Ãß´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç Á¦°ø¾÷ü ½ÃÀåÀº ÀǾàǰ ÀÓ»ó½ÃÇè¿¡ AI¸¦ Ȱ¿ëÇÏ´Â ¿©·¯ ¿¬±¸Àڵ鿡 ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
AI Ȱ¿ë ÀÓ»ó½ÃÇè °ü¸® ½ÃÀåÀÇ Áö¸®Àû Àü¸Á
ÀΰøÁö´É °ü·Ã ±â¼ú ¹ßÀü°ú Çõ½Å¿¡ ÀÖ¾î ºÏ¹Ì, ƯÈ÷ ¹Ì±¹Àº ¼¼°è ÃÖ÷´ÜÀ» ´Þ¸®°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ÀÇ·á ¿¬±¸ ¹× °Ç° ºÐ¾ß¿Í °°Àº ´Ù¾çÇÑ »ê¾÷À» À§ÇÑ ÃÖ÷´Ü AI ´äº¯À» ÁغñÇÏ´Â µ¥ ÁÖ·ÂÇÏ´Â ¼±µµÀûÀÎ Á¤º¸ ±â¼ú ±â°ü, ÇнÀ ±â°ü ¹× ½Å»ý ±â¾÷ÀÌ ¸¹ÀÌ ÀÖÀ¸¸ç, AI ±â¾÷ ¹× ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡ ¸¹Àº Àڱݰú Àç·á°¡ ÇÒ´çµÇ¾î ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀ» Æ÷ÇÔÇÑ ÇコÄÉ¾î ¼ºñ½º¿¡¼ AI ±â¼úÀÇ Ã¢Ãâ°ú Ȱ¿ë¿¡ °ü½ÉÀ» º¸ÀÌ´Â ÀÚº» º¥Ã³, °ø°ø ºÎ¹® ¹× °³ÀÎ ±ÝÀ¶ ±â°üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¸¦ ±¸¸ÅÇØ¾ß ÇÏ´Â ÀÌÀ¯
±â¾÷Àº ¾î¶² ¸ñÀûÀ¸·Î ¿ì¸®ÀÇ º¸°í¼¸¦ »ç¿ëÇϳª¿ä?
»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¸®Àû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ
The AI-powered clinical trial management market is expected to grow at a CAGR of 22.50%, reaching a market size of US$4.950 billion in 2029 from US$1.794 billion in 2024.
The market for using AI in healthcare has experienced a significant boom with a rise in the adoption of AI by the major players. The AI-driven clinical trial management market speeds up and improves various stages of clinical trials via patient recruitment, data analysis, and protocol optimization. AI makes drug development more efficient, cheaper, and quicker by automating repetitive tasks and providing predictive insights. This revolutionary technology can change the entire process of medical research, enabling more accurate, swift decisions. Due to increasing uptake by pharmaceutical companies, research institutions, and healthcare providers of AI-based solutions, this market is expected to grow substantially, transforming its landscape and eventually improving patient care.
The market for providers of AI-based clinical trial solutions is being driven by the growing adoption of AI-based platforms to enhance the efficiency and effectiveness of trials at different stages. One factor driving the market expansion is the public and private sectors' supportive initiatives for various therapeutic areas. Additionally, the market is growing due to the increased awareness and various uses of AI in clinical trials, including better patient selection, site selection, drug trial design, patient monitoring, and more.
As a result of the growing application of artificial intelligence to drug trials and the availability of different AI solutions designed specifically for pharmaceutical research, such as medication compliance, trial design, selection of investigators or sites, patient monitoring, etc., the area offering AI-based clinical trial solutions is widening. Enrollment and patient eligibility are two crucial processes for the overall success of the medication trial. According to studies, 30% of medication trials end early because of patient recruitment failure, and 85% of trials are postponed during patient recruitment. Platforms with an AI component are helping to lower this barrier. In turn, the market for AI-based clinical trial solution providers is driven by several researchers utilizing AI in drug trials.
AI-powered Clinical Trial Management Market Geographical Outlook
Regarding technological progress and innovation concerning artificial intelligence, North America, particularly the United States, has been at the forefront of the world. Numerous premier information technology organizations, learning institutions, and start-ups focused on preparing state-of-the-art AI answers for various industries, such as medical research or the health sector, are found in this region. A lot of funds and materials have been allocated to AI companies as well as research projects. More capital ventures, public sectors, and individual financiers have expressed their interest in creating and utilizing AI technologies in healthcare services, including clinical trials.
Reasons for buying this report:-
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence